Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMMB Chemomab Therapeutics	$0.89 +0.6%	$1.09	$0.87 ▼ $2.55	$16.78M	0.52	114,253 shs	302,411 shs
HOTH Hoth Therapeutics	$1.30 +0.8%	$1.29	$0.65 ▼ $3.80	$17.24M	0.66	229,682 shs	151,135 shs
LIXT Lixte Biotechnology	$3.41 +3.0%	$3.12	$0.64 ▼ $5.14	$15.55M	0.43	141,948 shs	131,021 shs
PWUP PowerUp Acquisition	$0.55 +1.7%	$0.36	$8.05 ▼ $15.80	$71.75M	0.05	3,464 shs	4.30 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMMB Chemomab Therapeutics	0.00%	-4.30%	-18.35%	-34.80%	-27.05%
HOTH Hoth Therapeutics	0.00%	+1.56%	0.00%	+52.22%	+85.58%
LIXT Lixte Biotechnology	0.00%	-5.01%	-20.51%	+158.33%	+86.34%
PWUP PowerUp Acquisition	+1.66%	+52.12%	+31.53%	+142.71%	-95.14%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CMMB Chemomab Therapeutics	3.4836 of 5 stars	3.5	5.0	0.0	0.0	3.3	1.7	0.6
HOTH Hoth Therapeutics	2.4541 of 5 stars	3.5	5.0	0.0	0.0	1.0	0.0	0.6
LIXT Lixte Biotechnology	0.0493 of 5 stars	0.0	2.0	0.0	0.0	0.0	0.8	0.0
PWUP PowerUp Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CMMB Chemomab Therapeutics	3.00	Buy	$8.50	855.06% Upside
HOTH Hoth Therapeutics	3.00	Buy	$4.00	207.69% Upside
LIXT Lixte Biotechnology	0.00	N/A	N/A	N/A
PWUP PowerUp Acquisition	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest PWUP, CMMB, LIXT, and HOTH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
7/30/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
7/23/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/26/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/12/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	$0.51 per share	N/A
HOTH Hoth Therapeutics	N/A	N/A	N/A	N/A	$0.73 per share	N/A
LIXT Lixte Biotechnology	N/A	N/A	N/A	N/A	$0.14 per share	N/A
PWUP PowerUp Acquisition	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CMMB Chemomab Therapeutics	-$13.94M	-$0.59	N/A	N/A	N/A	N/A	-94.71%	-76.53%	N/A
HOTH Hoth Therapeutics	-$8.19M	-$1.07	N/A	N/A	N/A	N/A	-114.32%	-105.92%	11/11/2025 (Estimated)
LIXT Lixte Biotechnology	-$3.59M	-$1.29	N/A	∞	N/A	N/A	N/A	-222.90%	11/10/2025 (Estimated)
PWUP PowerUp Acquisition	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest PWUP, CMMB, LIXT, and HOTH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CMMB Chemomab Therapeutics	-$0.20	-$0.09	+$0.11	-$0.09	N/A	N/A
8/12/2025	Q2 2025	HOTH Hoth Therapeutics	-$0.27	-$0.17	+$0.10	-$0.17	N/A	N/A
8/7/2025	Q2 2025	LIXT Lixte Biotechnology	N/A	-$0.29	N/A	-$0.29	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	N/A
HOTH Hoth Therapeutics	N/A	N/A	N/A	N/A	N/A
LIXT Lixte Biotechnology	N/A	N/A	N/A	N/A	N/A
PWUP PowerUp Acquisition	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CMMB Chemomab Therapeutics	N/A	7.42	5.33
HOTH Hoth Therapeutics	N/A	27.54	27.54
LIXT Lixte Biotechnology	N/A	1.84	1.84
PWUP PowerUp Acquisition	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CMMB Chemomab Therapeutics	46.05%
HOTH Hoth Therapeutics	7.08%
LIXT Lixte Biotechnology	5.10%
PWUP PowerUp Acquisition	19.17%

Insider Ownership

Company	Insider Ownership
CMMB Chemomab Therapeutics	11.91%
HOTH Hoth Therapeutics	6.92%
LIXT Lixte Biotechnology	14.80%
PWUP PowerUp Acquisition	48.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CMMB Chemomab Therapeutics	20	18.86 million	16.61 million	Not Optionable
HOTH Hoth Therapeutics	4	13.26 million	12.34 million	Not Optionable
LIXT Lixte Biotechnology	4	4.56 million	3.89 million	Not Optionable
PWUP PowerUp Acquisition	N/A	7.77 million	4.04 million	Not Optionable

PWUP, CMMB, LIXT, and HOTH Headlines

Recent News About These Companies

Aspire Biopharma, Inc.: Aspire Biopharma Holdings, Inc., Announces Public Listing on Nasdaq

February 20, 2025 | finanznachrichten.de

Aspire Biopharma, PowerUp Acquisition complete business combination

February 20, 2025 | markets.businessinsider.com

Aspire Biopharma announces public listing on Nasdaq

February 20, 2025 | markets.businessinsider.com

Aspire Biopharma Holdings, Inc., Announces Public Listing on Nasdaq

February 20, 2025 | accessnewswire.comA

Aspire Biopharma Holdings, Inc., Announces Public Listing on Nasdaq

February 19, 2025 | accessnewswire.comA

(PWUP) Technical Pivots with Risk Controls

February 13, 2025 | news.stocktradersdaily.comN

PowerUp Acquisition Corp trading resumes

February 12, 2025 | markets.businessinsider.com

PowerUp Acquisition Corp trading halted, volatility trading pause

February 12, 2025 | markets.businessinsider.com

PowerUp Stock Soars to All-Time High of $14.84 Amidst Strong Growth

February 11, 2025 | msn.com

PowerUp Acquisition Corp. Approves Merger with Aspire Biopharma

February 11, 2025 | msn.com

When (PWUP) Moves Investors should Listen

February 2, 2025 | news.stocktradersdaily.comN

PowerUp Acquisition Corp. Cl A

January 17, 2025 | wsj.com

How to Take Advantage of moves in (PWUP)

January 12, 2025 | news.stocktradersdaily.comN

PWUP PowerUp Acquisition Corp.

December 12, 2024 | seekingalpha.com

How To Trade (PWUP)

November 19, 2024 | news.stocktradersdaily.comN

When the Price of (PWUP) Talks, People Listen

October 18, 2024 | news.stocktradersdaily.comN

SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers of PWUP and ESGR

October 9, 2024 | prnewswire.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K, PWUP, RVNC, ESGR on Behalf of Shareholders

October 8, 2024 | stockhouse.com

SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers of PWUP, ESGR

October 7, 2024 | accesswire.comA

(PWUPU) Investment Analysis

September 26, 2024 | news.stocktradersdaily.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

PWUP, CMMB, LIXT, and HOTH Company Descriptions

Chemomab Therapeutics NASDAQ:CMMB

$0.89 +0.01 (+0.56%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$0.87 -0.02 (-2.25%)

As of 08/22/2025 07:59 PM Eastern

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Hoth Therapeutics NASDAQ:HOTH

$1.30 +0.01 (+0.78%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.26 -0.04 (-2.69%)

As of 08/22/2025 07:59 PM Eastern

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.

Lixte Biotechnology NASDAQ:LIXT

$3.41 +0.10 (+3.02%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$3.50 +0.09 (+2.49%)

As of 08/22/2025 06:53 PM Eastern

LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.

PowerUp Acquisition NASDAQ:PWUP

$0.55 +0.01 (+1.66%)

As of 08/22/2025

PowerUp Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on video gaming, gaming adjacent, and metaverse businesses. PowerUp Acquisition Corp. was incorporated in 2021 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time